Table 2 Reasons for discontinuation of abatacept infusion in the abatacept monotherapy group and the abatacept plus conventional DMARDs group
Abatacept monotherapy (n = 46) | Abatacept + conventional DMARD (n = 90) | |
|---|---|---|
Primary ineffectiveness, n (%) | 19 (41.3 %) | 40 (44.4 %) |
Therapeutic escape, n (%) | 3 (6.6 %) | 9 (10 %) |
Infusion reaction, n (%) | 2 (4.3 %) | 1 (1.1 %) |
Other side effects, n (%) | 4 (8.7 %) | 6 (6.7 %) |
Unknown, n (%) | 18 (39.1 %) | 34 (37.8 %) |